Covid-19: Delhi left with 1 day Covaxin stock for people aged 45 and above

While Covishield stock will last for five days for the same group of beneficiaries, AAP MLA Atishi Marlena informed on Sunday

Covaxin
(Photo: Bloomberg)
ANI General News
2 min read Last Updated : May 17 2021 | 7:59 AM IST

Delhi has only one day of COVID-19 vaccine Covaxin sock left for beneficiaries aged 45 years and above, while Covishield stock will last for five days for the same group of beneficiaries, Aam Aadmi Party (AAP) MLA Atishi Marlena informed on Sunday.

Marlena also said that Covaxin has not been administered to the beneficiaries of age group 18-44 for five days and stock of Covishield reserved for the 18-44 age group is left for six days.

"Delhi is left with 2,91,780 COVID-19 vaccine doses in its balance stock reserved for the age group 18-44 years out of which 4,550 doses are of COVAXIN and 2,87,230 of Covishield," the AAP MLA said.

As for the COVID vaccine supply reserved for people above 45 years of age, frontline workers and healthcare workers, a total of 3,25,480 doses are left. Out of the balance stock, 76,350 doses of Covaxin and 2,49,130 doses of Covishield are left.

The AAP MLA further said that as many as 1,18,043 vaccine doses were administered in the last 24 hours. The cumulative COVID-19 vaccine doses administered stands at 44,90,791.

"Since we have exhausted the Covaxin stock for beneficiaries of the age group 18-24 category, all such vaccination centres have been shut. We have six days of COVISHIELD stock left," she added.

According to the health bulletin by the Delhi government, the national capital witnessed a further dip in positivity rate and reported 6,456 new COVID-19 cases in the last 24 hours.

The national capital registered 262 deaths in the last 24 hours. The death toll in Delhi has mounted to 21,506, while the cumulative fatality rate has increased to 1.55 per cent.

The total case count in the city stands at 13,93,867, including 62,783 active cases.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus VaccineDelhi

First Published: May 17 2021 | 7:47 AM IST

Next Story